{
  "id": 8164147,
  "title": "Travere therapeutics CEO Eric Dube sells $25.4m in shares",
  "url": "https://urgent.news/2026/09/18/travere-therapeutics-ceo-eric-dube-sells-25-4m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T03:31:09.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/travere-therapeutics-ceo-eric-dube-sells-254m-in-shares-93CH-4906651"
  },
  "original_language": "en",
  "account": null,
  "summary": "Travere Therapeutics CEO Eric Dube sold $25.4 million worth of company shares over a three-day period in September 2026, exercising employee stock options and subsequently selling all 400,000 shares at prices ranging from $61.99 to $65.31. The stock had surged 168% over the previous year, leading to speculation that the sales were made in anticipation of the stock's overvaluation. Meanwhile, Travere Therapeutics reported robust financial results for Q2 2026, with revenue reaching $169.6 million, driven by a 96% increase in FILSPARI sales to $141.1 million. The company's confidence in the early uptake of its newly launched drug for FSGS and the positive progress of payer access further indicate a period of significant growth for the company.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Crowdstrike CEO George Kurtz sells $4.85m in CRWD shares",
        "url": "https://urgent.news/2026/09/18/crowdstrike-ceo-george-kurtz-sells-4-85m-in-crwd-shares",
        "published": "2026-09-18T02:15:57.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}